Sinovac Biotech Ltd., a biopharmaceutical company, focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases in China. Its portfolio of regulatory-approved products consists of vaccines against the hepatitis A, hepatitis B and influenza viruses. The company offers Healive, an inactivated hepatitis A vaccine; Bilive, a combination hepatitis A and B vaccine; Anflu, a split virus influenza vaccine; and Panflu, a vaccine against the H5N1 influenza virus. The company?s pipeline vaccine candidates in the pre-clinical and clinical development phases include human vaccines for Enterovirus 71, Japanese encephalitis virus, and rabies; a vaccine for the SARS virus, which completed Phase I clinical trial; animal rabies vaccine; and a split viron vaccine for the H5N1 influenza virus, which completed Phase II clinical trial. It markets and sells its vaccine products primarily through various provincial and municipal centers for disease control and prevention. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People?s Republic of China.